Albumin의 후향적 약물 사용 평가

홍주희,이영희,정선회,박경호,손인자 韓國病院藥師會 2004 병원약사회지 Vol.21 No.2

Albumin is used in hypovolemic shock, severe burns, acute hypoproteinemia, adult respiratory distress syndrome, and cardiopulmonary bypass. But the high cost of albumin relative to less expensive alternatives, such as nonprotein colloid(eg, hetastarch, dextran) and crystalloic solution (eg, lactated Ringer’s solution, various sodium chloride solutions), has intensified the debate surrounding the appropriate clinical use of resuscitation fluids. This study was performed to analyzed the appropriateness for albumin use and conducted through retrospective chart review of one hundred and seven inpatients who received albumin in Seoul National University Hospital for Aug. 2003. We applied the ASHP DUE criteria which is composed of justification of use, critical indicators, complications and outcome measures. As a result, 104 cases(59.1%) met with the criteria for justification of use. In analysis critical indicators, measurement of plasma albumin and total protein within 1 day before beginning albumin therapy and daily thereafter was acceptable 95 cases(54%). But administration rate adjustment could not observed, because of a lack of records. As an outcome analysis, plasma albumin and total protein after albumin administration was elevated in 85 cases(48.3%). Definite complications in albumin use were none. In this research the use of albumin showed adequate justification of use but low in the critical indicators except plasma albumin and total protein monitoring. The uses of albumin require improvement in monitoring for patients’general condition and fundamental therapy for hypoalbuminemia.

Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors

Hyun, Hyesun,Park, Joonyoung,Willis, Kiela,Park, Ji Eun,Lyle, L. Tiffany,Lee, Wooin,Yeo, Yoon Elsevier 2018 Biomaterials Vol.180 No.-

<P><B>Abstract</B></P> <P>Albumin is a promising surface modifier of nanoparticulate drug delivery systems. Serving as a dysopsonin, albumin can protect circulating nanoparticles (NPs) from the recognition and clearance by the mononuclear phagocytic system (MPS). Albumin may also help transport the NPs to solid tumors based on the increased consumption by cancer cells and interactions with the tumor microenvironment. Several studies have explored the benefits of surface-bound albumin to enhance NP delivery to tumors. However, it remains unknown how the surface modification process affects the conformation of albumin and the performance of the albumin-modified NPs. We use three different surface modification methods including two prevalent approaches (physisorption and interfacial embedding) and a new method based on dopamine polymerization to modify the surface of poly(lactic-co-glycolic acid) NPs with albumin and compare the extent of albumin binding, conformation of the surface-bound albumin, and biological performances of the albumin-coated NPs. We find that the dopamine polymerization method preserves the albumin structure, forming a surface layer that facilitates NP transport and drug delivery into tumors via the interaction with albumin-binding proteins. In contrast, the interfacial embedding method creates NPs with denatured albumin that offers no particular benefit to the interaction with cancer cells but rather promotes the MPS uptake via direct and indirect interactions with scavenger receptor A. This study demonstrates that the surface-bound albumin can bring distinct effects according to the way they interact with NP surface and thus needs to be controlled in order to achieve favorable therapeutic outcomes.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>

요 알부민 측정에서 DiaSys Albumin in Urine/CSF FS 시약의 JEOL BioMajesty JCA-BM6010/C 기기에서 분석능 평가

김현정,지미숙,문희원,허미나,윤여민 대한진단검사의학회 2016 Laboratory Medicine Online Vol.6 No.2

Background: High albuminuria is defined as albumin excretion of >30 mg/24 hr or an albumin-to-creatinine ratio of 30 mg/g in a random urine sample. We assessed the analytical performance of the Albumin in Urine/CSF FS kit (DiaSys Inc., UK) using a BioMajesty JCA-6010/C analyzer (JEOL Inc., Japan). Methods: Urine albumin concentrations were measured by the Albumin in Urine/CSF FS kit using a BioMajesty JCA-BM6010/C analyzer. Imprecision, linearity, and carry-over were measured according to the Clinical Laboratory and Standards Institute documents EP10 and EP9. The assay was compared with the ALB-T TQ Gen.2 (Roche, Germany) assay on a Cobas8000 C702 (Roche, Germany), the Tina-Quant Albumin (Roche, Switzerland) assay on a Hitachi7600-210 (Hitachi, Japan), and an Abbott urine albumin assay (Abbott Laboratories, USA) on a TBA 200FR (Toshiba, Japan) using 50 random urine samples. Results: Within-run and total imprecision were 0.551-1.023% and 0.551-1.214%, respectively. Linearity ranged from 6.31 to 30.60 mg/dL, and functional sensitivity was 0.5 mg/dL. Results from the Albumin in Urine/CSF FS kit showed good correlation with the ALB-T TQ Gen.2 (r=0.987) and the Tina-Quant Albumin assays (r=0.991). However, the four assays categorized 18 of 50 urine samples into different albuminuria groups. Conclusions: Albumin in Urine/CSF FS testing on a BioMajesty JCA-BM6010/C analyzer showed good linearity, functional sensitivity, precision, and correlation with the ALB-T TQ Gen.2 and Tina-Quant Albumin assays. However, because some samples were categorized into different albuminuria groups by the different assays, further studies on the standardization of albuminuria assays are needed. 배경: 고알부민뇨증은 24시간 요에서 알부민의 배설이 30 mg 이상 또는 임의뇨에서 크레아티닌에 대한 알부민의 농도가 30 mg/g 이상인 경우로 정의된다. 저자들은 Albumin in Urine/CSF FS (DiaSys Inc., UK) 시약의 BioMajesty JCA-6010/C analyzer (JEOL Inc., Japan) 장비에서의 분석능을 평가하였다. 방법: 요 알부민 농도는 BioMajesty JCA-BM6010/C 장비에서 Albumin in Urine/CSF FS 시약으로 측정되었다. 평가는 정도관리물질을 사용하여 CLSI EP10과 EP9에 따라 비정밀도, 직선성, 잔효를 포함하였다. 이 검사방법은 50개의 임의뇨 검체를 이용하여 Cobas8000 C702 (Roche, Germany) 장비에서 ALB-T TQ Gen.2(Roche, Germany) 시약, Hitachi7600-210 (Hitachi, Japan) 장비에서 Tina-Quant Albumin (Roche, Switzerland) 시약, 그리고 TBA 200FR (Toshiba, Japan) 장비에서 Abbott urine albumin assay (Abbott Laboratories, USA) 시약을 이용한 검사방법과 비교하였다. 결과: 3개의 정도관리물질을 이용한 검사차례 내 그리고 총 비정밀도는 각각 0.551-1.023%와 0.551-1.214%였다. 직선성은 6.31부터 30.60 mg/dL까지 관찰되었고, 기능적 민감도는 0.5 mg/dL였다. BioMajesty JCA-BM6010/C에서 Albumin in Urine/CSF FS 시약의 검사방법은 Cobas8000 C702에서 ALB-T TQ Gen.2 시약의 검사법 및 Hitachi7600-210에서 Tina-Quant Albumin 시약의 검사법과 우수한 상관관계를 보였다. 그러나 네 개 검사법은 50개의 요검체 중 18검체를 서로 다른 알부민뇨 그룹으로 분류하였다. 결론: BioMajesty JCA-BM6010/C 장비에서 Albumin in Urine/CSF FS 시약의 검사방법은 우수한 직선성, 기능적 민감도, 비정밀도를 보였고, Cobas8000 C702에서 ALB-T TQ Gen.2를 사용하는 경우와 Hitachi 7600-210에서 Tina-Quant Albumin을 사용하는 검사법과 우수한 상관관계를 보여주었다. 그러나, 각각의 검사방법에 의해 50개의 검체 중 상당수가 다른 알부민뇨 그룹으로 분류되었기 때문에, 알부민뇨에 대한 앞으로의 연구와 검사 제품 간의 표준화에 대한 연구가 더 필요할 것으로 생각하였다.

Human Serum Albumin에 대한 단세포군 항체의 생성, 특성분석 및 microalbuminuria 검색을 위한 sandwich ELISA의 개발에 관한 연구

구자욱,고광욱,고재경 한양대학교 의과대학 1992 한양의대 학술지 Vol.12 No.1

Alumin of a variety of species has been the subject of extensive studies by protein chemists and immunologists for over 3 deades. Human serum albumin (HSA) is the most abundant protein in plasma. It is a nonglycosylated protein consisting of a single polypeptide chain of 585 amino acids with 34 cystive residues. The molecule contains 9 serial double loops formed by 17 disulfide bridges arranged as 3 repeat units or domains. Since polyclonal antibodies bind to almost all antigenic determinants of antigen, the experiments base4d on polyclonal antibodies yielded frequently low-titre, of broad specificity, and are not completely reproducible, although the heterogeneity of fine specificity could be minimized by affinity chromatography on fragments of the immunogens. Recently, the development of hybridoma techniques has made it possible to produce a large amount of homogenous and specific anti-protein antibody which reacts with a single epitope of antigen. Diabetic nephropathy is the major cause of the increased mortality in insulin-dependent diabetes mellitus (IDDM), affecting over 40% of these patients. Recent studies have shown that an increased urinary albumin excretion rate (microalbuminuria) in IDDM patients is a good predictor of the development of diabetic nephropathy. The possibility that therapeutic intervention instituted at this early stage of the disease might reverse, arrest or at least slow its progression to late and irreversible stages promotes the necessity to develop a screening test for microalbuminuria. Microalbuminuria can be measured by radioimmunoassay(RIA), nephelometric laser, immunoturbidimetry and enzyme linked immunosorbent assay(ELISA). However, RIA has some disadvanges such as isotope-related health hazards, and expense of equipment used to measure gamma-emitting isotope. The aims in this study were to produce monoclonal antibodies against HSA and to develop a simple, rapid, and sensitive sandwich ELISA using anti-human albumin monoclonal antibodies for detecting microalbuminuria. Four monoclonal antibodies(MHA-1, MHA-2, MHA-3, and MHA-4) which reacted selectively against HSA were produced by hybridoma technology. Isotype of each monoclonal antibody was found to be IgG₁. All monoclonal antibodies except MHA-1 were species-specific which were demonstrated on ELISA and immunoblotting. Since MHA-4 reacted with albumin in only nonreducting condition, it was suggested that this antibody recognized the conformational epitope of the albumin. Utilizing ingibition ELISA, it was speculated that these four antibodies recognized respectively 4 different epitopes of albumin and among those epitopes, epitopes of MHA-2 and MHA-3 same or located very approximately. Sandwich ELISA using two monoclonal antibodies(MHA-4 as capture antibody and MHA-2 as detector antibody), which reacted with different epitopes, were developed to detect microalbuminuria. Dynamic range of this assay was from 30 to 5000㎍/1 and its lowere limit of detection was 30㎍/1, corresponding to 1.5ng of albumin per well. The intra-assay and the inter-assay coefficient of variation were 3.3-4.0% and 6.8-8.0%, respectively. Analytical recovery ranged from 92 to 103%. Concentrations of 84 urine samples were measured by the sandwich ELISA and competitive RIA. Correlation between two assays was good(r=0.983, p<0.005) over a range of albumin concentration tested. Albumon excretions in 24 hour urine samples from non-insulin-dependent diabetes mellitus(NIDDM) patients (mean 16.7mg/day, n=39, 8yr duration) were significantly increased (t=2.53, p=0.015) as compared with those from healthy subjects(mean 5.6mg/day). However, 24 hour urine albumin excretions in IDDM patient(mean 11.1mg/day, n=25, 6.8yr duration) werer not significantly different from those in normal control(t=1.16, p=0.26). The 24 hour urine albumin(mg/day) correlated well with the urine albumin/creatinine ratio(r=0.816, p<0.005) on log data. This study indicates that this newly established sandwich ELISA is found to have good analytical characteristics, outstanding in its specificty, sensitivity, accuracy, and precision, and is suitable and easily accessable for detection of microalbuminuria in clinical medicine.

BCAA와 OKG 및 Albumin 가중 투여가 장시간 운동 시 피로물질요인과 에너지기질에 미치는 영향

조수연 ( Su Youn Cho ),백일영 ( Il Young Paik ),우진희 ( Jin Hee Woo ),김근수 ( Keun Su Kim ) 한국스포츠정책과학원(구 한국스포츠개발원) 2004 체육과학연구 Vol.15 No.3

본 연구의 목적은 BCAA와 OKG 및 albumin 가중투여가 장시간의 운동 시 혈중 피로물질변화와 에너지기질 동원에 미치는 영향을 규명하는데 있다. 연구 대상자는 남자 대학생 5명으로 하였으며 8주간 실험을 실시하였다. 피험자 5명은 각각의 투여방법에 따른 실험에 모두 참여하였으며, 투여 실험의 순서는 비투여(control), BCAA, BCAA+OKG, BCAA+albumin 순으로 하였다. 모든 투여방법의 실험 시 운동은 트레드밀을 이용하여 90분동안 달리기를 시행하였으며, 운동 강도는 속도 5mph, 경사도 3%로 설정하였다. 혈액은 운동 전, 운동 45분, 종료 시, 회복 30분에 채혈하고, 채혈된 혈액으로 혈중 피로물질인 암모니아, 5-HT, 젖산, 무기인산염 그리고 에너지기질인 글루코스와 유리지방산의 농도 변화를 분석하였다. 중추 피로요소인 암모니아 농도는 모든 시기에서 control군과 BCAA투여군에 비해 BCAA+OKG 투여군과 BCAA+ albumin 투여군이 낮게 나타났으며, BCAA +albumin 투여군이 가장 낮았고, BCAA 투여군이 가장 높게 나타났다. 5-HT는 운동 전에서 운동 45분까지 control군과 BCAA 투여군이 BCAA+OKG 투여군과 BCAA +albumin 투여군에 비해 높은 농도를 보였다. 그러나 운동 90분에는 BCAA+albumin 투여군이 가장 높았고 BCAA+OKG 투여군이 가장 낮게 나타났다. 말초 피로요소인 젖산은 전반적으로 BCAA 투여군이 가장 높았으며 BCAA+OKG와 BCAA+albumin 투여군이 낮은 경향을 보였다. 에너지기질인 글루코스의 혈중농도는 전반적으로 control군이 가장 높았고, BCAA+albumin 투여군이 가장 낮았으며, 운동 시기 간에 유의한 차이가 있었다(p<.05). 유리지방산의 혈중 농도는 모든 시기에서 BCAA+albumin 투여군이 가장 높았고, BCAA 투여군이 가장 낮았으며, 투여군 간과 운동 시기 간 모두 유의한 차이가 나타났다(p<.05). 이상의 연구 결과, 운동 수행에 부정적 영향을 미칠 수 있는 BCAA 단독 투여와는 달리 OKG나 albumin 가중투여는 BCAA 단독 투여시 나타날 수 있는 피로물질 축적의 감소를 가져올 뿐 아니라, 장기간 운동 시 BCAA가 에너지기질로 사용될 수 있게 함으로써, 운동수행에 이로운 영향을 미칠 수 있다고 볼 수 있으며, 특히 BCAA+albumin 투여가 가장 효과적인 것으로 사료된다. Purpose: The purpose of this study was to investigate the effects of BCAA and additional OKG or albumin supplements on fatigue factors and energy substrates changes in prolonged exercise. Methods: The subjects of this study were 5 male college students and the order of experiments was control, BCAA, BCAA+OKG, BCAA+ albumin. In each experiment, the subject ran for 90 minutes on the treadmill and exercise intensity was 3% gradient and 5mph. Blood was drawn five times; before the exercise, after 45 minutes of exercise, end of exercise, and 30minutes after ending of exercise. Blood was used to analyze ammonia, 5-HT, lactate, glucose and FFA. Results: The concentration of blood ammonia was low in the BCAA+OKG and BCAA+albumin groups compared to control and BCAA groups. And, lowest in the BCAA+albumin supplement group during exercise and recovery. The 5-HT concentration of control and BCAA supplement groups represented higher than BCAA+OKG and BCAA+albumin groups from resting to 45 min of exercise. However, at 90 min of exercise, BCAA+albumin group was highest, but BCAA+OKG was the lowest. The concentration of lactate was the highest in the BCAA supplement group, but represented low tendency in the BCAA+OKG and BCAA+albumin supplement group at the end of exercise and recovery. In glucose, control group was the highest, but BCAA+albumin supplement group was the lowest at the end of exercise and recovery. The concentration of FFA was the highest in the BCAA+albumin supplement group, but was the lowest in the BCAA supplement group at the 45 min and 90 min of exercise. Conclusion: As the result of this study was shown, BCAA and additional OKG or albumin can solve these problems that BCAA accumulate fatigue factors when it is oxidized. Furthermore, BCAA can be used as energy substrate when OKG or albumin is added to BCAA. Therefore, it is considered that BCAA and additional OKG or albumin supplement has effects on prolonged exercise. Specially, we are considered by thing which BCAA+albumin supplement is the most effect.

혈청 알부민 나노입자를 이용한 항생제 흡착

김현지(Hyunji Kim),임성인(Sung In Lim) 한국청정기술학회 2021 청정기술 Vol.27 No.1

항생제는 감염병 환자의 치료, 농수축산업의 생산성 향상을 위한 목적으로 광범위하게 사용되는 약물이다. 그러나 항생제 과용 및 낮은 생분해성으로 인해 상당량이 하수로 누출되어 환경오염을 유발하며 내성 박테리아 출현을 촉진하고 있다. 본 연구에서는 생분해성 혈청 단백질인 알부민을 항생제 흡착제로 사용하기 위한 가능성을 탐구하였다. 혈청 알부민은 다양한 대사산물과 호르몬을 모든 조직의 혈관 외 공간으로 운반하는 천연 혈액 단백질이다. 혈청 알부민은 수용성이 높지만 이온성, 친수성 또는 소수성 분자를 쉽게 수용하는 고유 결합 부위를 가지고 있어 나노 흡착제로 유망한 물질이다. 코아세르베이션(coacervation)을 유도하기 위해 탈용매제인 에탄올을 알부민 수용액에 적가하여 150 ~ 170 nm 크기 범위의 알부민 나노 입자로 탈수화 및 액-액분리 하였다. 글루타르알데히드 가교제를 첨가할 경우 알부민 나노입자의 크기 안정성 및 동질성이 증가하였다. 항생제 아목시실린에 대한 알부민 나노입자의 흡착능 평가에서 가교제 사용 농도, pH에 따른 흡착능의 차이가 관찰되었다. 분광광도법으로 측정한 알부민 나노입자의 단위질량당(mg) 최대 흡착능은 pH 4.0 수용액에서 아목시실린 12.4 마이크로그램(μg)이다. 이러한 결과는 물에서 항생제를 제거하는 천연 나노 흡착제를 제조하기 위한 구성 물질로서 혈청 알부민의 잠재력을 보여준다. Antibiotics are compounds broadly used to treat patients with infectious diseases and to enhance productivity in agriculture, fisheries, and livestock industries. However, due to the overuse of antibiotics and their low biodegradability, a substantial amount of antibiotics is leaking into the sewer, subsequently resulting in pollution and the emergence of antibiotic-resistant bacteria. This study explores biodegradable serum albumin’s potential as an adsorbent to remove antibiotics from water. Serum albumin is a natural blood protein that transports various metabolites and hormones to all tissues’ extravascular spaces. While serum albumin is highly water-soluble, it has intrinsic binding sites which readily accommodate ionic, hydrophilic, or hydrophobic molecules, rendering it a good building block for a nano-adsorbent. To induce coacervation, a desolvating agent, ethanol, was added dropwise into the aqueous albumin solution, resulting in dehydration and liquid-liquid phase separation of albumins into albumin nanoparticles within a size range of 150 ~ 170 nm. The addition of glutaraldehyde as a cross-linker improved the size stability and homogeneity of albumin nanoparticles. Adsorption of amoxicillin antibiotics on albumin nanoparticles was dependent upon glutaraldehyde concentration used in desolvation and pH during adsorption. The maximum adsorption capacity measured by spectrophotometry was found to be 12.4 micrograms of amoxicillin per milligram of albumin nanoparticle. These results demonstrate serum albumin’s potential as a building block for fabricating a natural nano-adsorbent to remove antibiotics from water.

Albumin: A Multi-talented Clinical and Pharmaceutical Player

Aziz Ullah,권혁택,임성인 한국생물공학회 2022 Biotechnology and Bioprocess Engineering Vol.27 No.5

Albumin is one of the copious and important plasma proteins which takes an active part in transporting therapeutic agents, neutralization of toxins, protection from inflammation, and maintenance of colloidal intravascular osmotic pressure. Moreover, the albumin is also involved in modulating the acid-base balance, maintenance of vascular endothelial integrity, and binding to a range of exogenous and endogenous compounds. The binding capability of the albumin helps in the transportation, delivery, and clearance of drugs and compounds outside of the body. Due to the marked biological and biochemical properties, the albumin is used in critical care and other clinical conditions as a plasma volume expander, replacement of fluids and nutrients loss, and restoration of albumin levels in hypoalbuminemic individuals. Clinical and pharmaceutical scientists are studying it rigorously to address various pathological conditions. The use of human serum albumin in the management of diseased conditions still needs to be more clarified which can be done by following the institutional clinical guidelines established after the mutual consensus of the clinical experts belonging to different medical backgrounds. In this review, the evidence-based clinical utilization of the albumin in different pathological conditions like hemorrhagic shock, decompensated liver cirrhosis, sepsis and septic shock, abdominal and cardiac surgery, acute brain injury, acute respiratory distress syndrome, and Alzheimer’s disease has been discussed. Furthermore, in addition to the role of albumin in cell therapy, the special features of the albumin as a pharmaceutical vehicle like cancer-specific targeting capability, surface modifiability, stealth property, and its use as a formulation stabilizer have been reviewed.

알부민이 첨가된 시험관내 약역학 감염모델을 이용한 폐렴알균 치료에서 Ceftriaxone 일일 1회 요법

허지안,전혜선,박선희,최수미,김시현,이동건,최정현,유진홍,신완식 대한감염학회 2006 감염과 화학요법 Vol.38 No.6

배경 : Penicillin 내성 폐렴알균이 증가하는 지역에서 대안 중의 하나로 사용되는 ceftriaxone (CTR)의 적절한 용법, 용량을 파악하는 것이 중요하다. 본 연구는 임상에서 분리된 폐렴알균을 대상으로 시험관내 약역학 감염모델을 이용하여 알부민이 첨가된 경우와 첨가되지 않은 경우 CTR의 일일 1회 요법의 효과를 비교해 보고자 하였다. 재료 및 방법 : Penicillin 감수성(SM24), 중간내성(SM47), 내성(SM60)주를 대상으로 2-구획 시험관내 약역학 감염모델을 적용하였다. CTR 주입은 2 g씩 24시간마다로 사람의 약동학을 모의하였다. 알부민은 모델에서 4g/ dL가 유지되도록 하였다. 살균효과는 0, 2, 4, 6, 24, 30, 48시간째 집락수 변화로 측정하였다. 결과 : 모든 균주에서 알부민이 첨가되지 않은 경우 6시간 이내에 살균력이 관찰되었다. 최저억제농도 및 알부민 첨가유무에 관계없이 3주 모두 24시간째 살균력이 관찰되었고, 48시간째는 모두 측정한계 이하의 집락수로 감소하였다. 전 실험과정에서 CTR에 대한 내성주는 출현하지 않았다. 결론 : CTR의 일일 1회 요법은 알부민이 첨가되었을 때, 감수성, 중간내성, 내성주 모두에서 살균력 발현이 지연되었으나 최종효과는 알부민이 없을 때와 다르지 않았다. 앞으로 알부민 결합효과와 관련된 기초적인 추가 연구가 필요할 것으로 생각된다. Background : During the era of increasing penicillin resistant Streptococcus pneumoniae, it is important to have knowledge about adequate dosage and dosing interval of ceftriaxone (CTR). We examined efficacies of once-daily CTR and compared results in an in vitro pharmacodynamic infection model (IVPDIM) supplemented with albumin and those without albumin. Methods : Using three clinically isolated S. pneumoniae that were susceptible (SM24), intermediate (SM47) and resistant (SM60) against CTR, we utilized a two-compartment IVPDIM. CTR 2 g was administered intravenously every 24 h. Human albumin was added with concentration of 4 g/dL. Samples were removed at multiple time points over a 48-h period to determine the colony counts. Results : In SM24 and SM60, bactericidal effects were observed within 6 hours in groups without albumin. The number of colonies during 1st 6 hours were more decreased in albumin-free groups than in albumin-supplemented groups (P<0.05). In SM47, similar results were found during 1st 6 hours (P=0.03). But, regrowth was observed in albumin supplemented group at 30 h. Irrespective of results of minimal inhibitory concentrations and albumin supplementation, bactericidal effects were shown at 24 h in all 3 strains. All groups were decreased below the detection limit at 48 h. Development of resistance was not detected throughout the entire study period in either strain. Conclusions : Although extents of killing in albumin supplemented broth of once-daily CTR dosing were delayed in all 3 strains compared with those of albumin free broth, final efficacies were not different between the two groups.

Loss of surface-Accociated Albumin during Capacitation and Acrosome Reaction of Mouse Epididymal Sperm in vitro

Gye, Myung Chan,Kim, Moon Kyoo 한국동물학회 1995 동물학회지 Vol.38 No.4

Prognostic Significance of Initial Serum Albumin on Mortality in Out-of-hospital Cardiac Arrest

박인원,김규석,조유환,김중희,김태윤,김유진,이진희,이중의,이재혁 대한응급의학회 2013 大韓應急醫學會誌 Vol.24 No.5

Purpose: The association of serum albumin concentration on hospital arrival with long-term mortality in survivors from out-of-hospital cardiac arrest (OHCA) was investigated. Methods: A retrospective analysis was conducted of patients presumed to have cardiac cause of arrest and achieved sustained return of spontaneous circulation (ROSC) from prospective OHCA. The individual medical records were reviewed for data, including initial serum albumin. The primary outcome was survival at 6 months and the secondary outcome was Cerebral Performance Category (CPC) at 6 months. Differences in variables between survivors and non-survivors at 6 months after cardiac arrest were analyzed. Albumin was categorized into tertiles of <2.9 g/dL, 2.9 to 3.7 g/dL, and >3.7 g/dL. Hazard ratios (HRs) were estimated using Cox-proportional hazard models in both univariate and multivariate analysis. All prognostic variables with p value<0.1 in univariate analysis were used in multivariate analysis for adjustment. Receiver operating curve (ROC) analysis was performed to evaluate the discriminative power of albumin. Results: In a total of 547 OHCA patients, 136 patients had a presumed cardiac cause of arrest and sustained ROSC with available initial serum albumin. The survival rate at 6months was significantly higher in patients in the higher albumin group and neurological outcomes were also more favorable in the higher albumin group (log rank test,p<0.05). In a Cox proportional hazard regression analysis,initial serum lactate and albumin levels were independently associated with 6-month mortality and albumin levels showed moderate discriminative power for 6-month mortality by ROC analysis (AUC=0.738, 95% CI: 0.652-0.825). Conclusion: Serum albumin is associated with long-term mortality and neurological outcome in patients with presumed cardiac cause of arrest and sustained ROSC from OHCA.